Sepracor president told analysts that Lunesta share nearing 40%

Share this article:
Sepracor president William O'Shea told analysts and investors that Lunesta's share of the sleep-aid market is nearing 40%, thanks to the company's aggressive direct-to-patient promotional efforts. The firm will now initiate “Phase Two” of its Lunesta promotion by increasing sales capacity and rolling out its expanded clinical database for the drug, he said in the company's first-half earnings report. The firm reported six-month Lunesta revenues of $277 million.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions